Last update 01 Nov 2024

BY101298

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [3]
Target
PRKDC
Mechanism
PRKDC inhibitors(DNA-dependent protein kinase inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Chengdu Baiyu Pharmaceutical Co. Ltd.Chengdu Baiyu Pharmaceutical Co. Ltd.
Active Organization
Chengdu Baiyu Pharmaceutical Co. Ltd.Chengdu Baiyu Pharmaceutical Co. Ltd.Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with BY101298
CTR20240701 / RecruitingPhase 1/2
一项评估BY101298联合放疗在恶性实体瘤患者中的安全性、耐受性、有效性和药代动力学特征的Ⅰb/Ⅱ期临床研究
[Translation] A Phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of BY101298 combined with radiotherapy in patients with malignant solid tumors
NCT06524804 / RecruitingPhase 1/2
A Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetic Characteristics of BY101298 Combined With Radiotherapy in Patients With Malignant Solid Tumors
ChiCTR2300070767 / SuspendedPhase 1IIT
A Phase I Clinical Study to Evaluate the Safety, Tolerance, and Pharmacokinetic Characteristics of BY101298 Single/Combined Radiotherapy in Patients with Malignant Solid Tumors
100 Clinical Results associated with BY101298
Login to view more data
100 Translational Medicine associated with BY101298
Login to view more data
100 Patents (Medical) associated with BY101298
Login to view more data
100 Deals associated with BY101298
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
CN
Chengdu Baiyu Pharmaceutical Co. Ltd.Chengdu Baiyu Pharmaceutical Co. Ltd.
19 Jul 2024
Advanced Malignant Solid NeoplasmPhase 2
CN
Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.
19 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free